Bromo is supposed to increase leptin isn't that what that new bromo book was about
I was going to deliver my usual cynical diatribe, but just to surprise georgie24 I'll be more upbeat. I have not read Lyle McDonald's book but I don't think it is leptin that dopamine is supposed to be targeting. Rather, bromocriptine, a dopamine agonist, "can reverse many of the metabolic alterations associated with obesity by resetting hypothalamic circadian organization of monamine neuronal activities" to quote the researchers at Ergo Science who pioneered this research.
What these guys noticed was that if bromocriptine is given to animals that usually store fat and then hibernate, they no longer store fat. Evidently this circadian fat storage phenomenon is somehow regulated by dopaminergic neuronal transmission. Leptin is not involved because when bromocriptine is administered to obese mice engineered to lack leptin, the mice still lose weight.
The Ergo people reasoned that humans might have a similar mechanism of fat storage and tried it on people. It seemed to work. Here is the relevant abstract:
Diabetes Care 1996 Jun;19(6):667-70
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Cincotta AH, Meier AH.
Ergo Science, Charlestown, Massachusetts 02129, USA.
OBJECTIVE: A double-blind placebo controlled study investigated long-term effects of Ergoset, a new quick release formulation of bromocriptine, on body weight, body fat, and glucose tolerance in a group (n = 17) of obese subjects who were instructed to follow a moderate hypocaloric diet. RESEARCH DESIGN AND METHODS: Obese individuals (> 25% body fat for men and > 30% body fat for women) were instructed to follow a calorie-restricted diet (70% of weight maintaining based on study entry weight) and were randomized to daily treatment with Ergoset (1.6-2.4 mg/day) or placebo at 0800 over an 18-week treatment period. Oral glucose tolerance tests were performed on subjects before initiation and again at termination of treatment. Body weight and body fat (determined by skinfold measurements) were quantified every 2 weeks during the course of treatment. RESULTS: Ergoset treatment for 18 weeks significantly reduced body weight and body fat versus placebo (6.3 +/- 1.5 and 5.4 +/- 1.1 kg vs. 0.9 +/- 1.0 and 1.5 +/- 0.6 kg. respectively, P < 0.01). Ergoset, but not placebo, also improved glucose tolerance (P < 0.02); the stimulated area under the oral glucose tolerance curve was reduced by 46% (from 121 +/- 23 to 64 +/- 32 mg.h-1.dl-1), while the stimulated area under the insulin curve was reduced by 30%. CONCLUSIONS: When combined with instruction to follow a moderate hypocaloric diet, Ergoset, but not placebo, improves glucose tolerance and promotes significant weight and body fat loss in obese subjects over an 18- week treatment period.